Evidence map›Paper›PMID 38962532›Full record

ArticleCancer diagnosis & prognosis

Attempt to Substitute the Oncotype DX Breast Recurrence Score

Yuka Nozaki, Yoshiya Horimoto, Ryoko Semba, Yuko Ueki, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Takahiko Kawate, Takashi Ishikawa, Junichiro Watanabe

Abstract read
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuka NozakiDepartment of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Yoshiya HorimotoDepartment of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Ryoko SembaDepartment of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Yuko UekiDepartment of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Yumiko IshizukaDepartment of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Hiroko OnagiDepartment of Human Pathology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Takuo HayashiDepartment of Human Pathology, Juntendo University Faculty of Medicine, Tokyo, Japan.
Takahiko KawateDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Takashi IshikawaDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Junichiro WatanabeDepartment of Breast Oncology, Juntendo University Faculty of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Oncotype DX Breast Recurrence Score Patients and Methods: Data from 114 Japanese women who underwent ODx were retrospectively examined to investigate the relationship between ODx recurrence score (RS) and clinicopathological features, including MUC1 staining patterns on immunohistochemical assessment. An RS of 0-25 was defined as low, and 26-100 as high. Results: Ninety patients (79%) had low RS and 24 patients (21%) had high RS. Univariate analysis revealed that low tumor grade, high progesterone receptor (PgR) expression, and low Ki67 labeling index (LI) were significantly associated with low RS (p=0.025, p<0.001, and p<0.001, respectively). Tumors with an apical pattern of MUC1 staining also frequently had a low RS (p=0.024). In multivariate analysis, PgR expression and Ki67 LI were independent factors associated with RS (p<0.001, for both). When the ODx results were categorized with a combination of these two factors, only 2% of the PgR-high and Ki67-low group (one in 51 cases) had a high RS. Conclusion: PgR expression and Ki67 LI were independent factors correlated with RS. MUC1 staining pattern also has the potential to be a useful marker. We believe that it is crucial to continue attempts to identify patients who are unlikely to benefit from ODx.

Indexed as

adjuvant chemotherapyBreast neoplasmsgene profiling assayintrinsic subtypeluminal typeMUC1oncotype DXrecurrence score

Identifiers

PMID38962532
PMCPMC11215451

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.